Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 2080-2090

  Pérot, Gaëlle ^a   Chibon, Frédéric ^b,c   Montero, Audrey ^b,c   Lagarde, Pauline ^b,c   De Thé, Hugues ^d   Terrier, Philippe ^e   Guillou, Louis ^f   Ranchère, Dominique ^g   Coindre, Jean Michel ^b,c   Aurias, Alain ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ALLELE; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENOMICS; GENOTYPE; LEIOMYOSARCOMA; NONHUMAN; P 14 GENE; P 15 GENE; P 16 GENE; PRIORITY JOURNAL; SARCOMA; SOFT TISSUE SARCOMA; TP 53 GENE; TUMOR SUPPRESSOR GENE;

EID: 77957371589     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100104     Document Type: Article

References (56)

1. Chibon F, Mariani O, Derré J, Malinge S, Coindre JM, Guillou L, Lagacé R, Aurias A: A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002, 139:24-29
2. Chibon F, Mariani O, Mairal A, Derré J, Coindre JM, Terrier P, Lagacé R, Sastre X, Aurias A: The use of clustering software for the classification of comparative genomic hybridization data. An analysis of 109 malignant fibrous histiocytomas. Cancer Genet Cytogenet 2003, 141:75-78
3. Coindre JM, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre-Guillevin E, Bui NB, Stoeckle E, Hostein I, Aurias A: Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003, 16:256-262
4. Derré J, Lagacé R, Nicolas A, Mairal A, Chibon F, Coindre JM, Terrier P, Sastre X, Aurias A: Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001, 81:211-215
5. Fletcher CDM, Unni KK, Mertens F: World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, IARC Press 2002
6. Mairal A, Terrier P, Chibon F, Sastre X, Lecesne A, Aurias A: Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet 1999, 111:134-138
7. Chibon F, Mairal A, Fréneaux P, Terrier P, Coindre JM, Sastre X, Aurias A: The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. Cancer Res 2000, 60:6339-6345
8. Otaño-Joos M, Mechtersheimer G, Ohl S, Wilgenbus KK, Scheurlen W, Lehnert T, Willeke F, Otto HF, Lichter P, Joos S: Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenet Cell Genet 2000, 90:86-92
9. Sandberg AA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet 2005, 161:1-19
10. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997, 121:395-399
11. Das P, Kotilingam D, Korchin B, Liu J, Yu D, Lazar AJ, Pollock RE, Lev D: High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 2007, 109:2323-2333
12. Soussi T, Ishioka C, Claustres M, Beroud C: Locus specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006, 6:83-90
13. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310
14. Efeyan A, Serrano M: p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007, 6:1006-1010
15. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275
16. Lowe SW, Sherr CJ: Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003, 13:77-83
17. Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602:73-87
18. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol 1999, 1:20-26
19. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, Berns A: p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007, 448:943-946
20. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001, 21:2144-2153
21. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346
22. Pérot G, Derré J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault L, Guillou L, Terrier P, Aurias A: Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 2009, 69:2269-2278
23. La Rosa P, Viara E, Hupé P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, Manié E, Brennetot C, Janoueix-Lerosey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delattre O, Aurias A, Radvanyi F, Barillot E: VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006, 22:2066-2073
24. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, Hanash S: Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics 2005, 6:26
25. Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH: High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009, 69:663-671
26. Iwato M, Tachibana O, Tohma Y, Arakawa Y, Nitta H, Hasegawa M, Yamashita J, Hayashi Y: Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. Cancer Res 2000, 60:2113-2115 (Pubitemid 30225169)
27. Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B: French Hereditary Melanoma Study Group: comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 2006, 43:39-47
28. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826
29. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, Yang CS: Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999, 5:2704-2713
30. Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Woodruff JM, Cordon-Cardo C: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994, 145:345-355 (Pubitemid 24245835)
31. Castresana JS, Rubio MP, Gómez L, Kreicbergs A, Zetterberg A, Barrios C: Detection of TP53 gene mutations in human sarcomas. Eur J Cancer 1995, 31A:735-738
32. Taubert H, Würl P, Meye A, Berger D, Thamm B, Neumann K, Hinze R, Schmidt H, Rath FW: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. Cancer 1995, 76:1187-1196
33. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53:2231-2234
34. Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9:701-713
35. Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009, 9:714-723
36. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T: A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007, 13:992-997
37. Orlow I, Drobnjak M, Zhang ZF, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C: Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst 1999, 91:73-79
38. Magdinier F, Wolffe AP: Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001, 98:4990-4995
39. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′- deoxycytidine. Cancer Res 2002, 62:6456-6461
40. Pollice A, Vivo M, La Mantia G: The promiscuity of ARF interactions with the proteasome. FEBS Lett 2008, 582:3257-3262
41. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM: Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell 2007, 26:843-852
42. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W: Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302:1972-1975
43. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N: mdmx is a negative regulator of p53 activity in vivo. Cancer Res 2002, 62:3221-3225
44. Krug U, Ganser A, Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002, 21:3475-3495
45. Murao K, Kubo Y, Ohtani N, Hara E, Arase S: Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways. Br J Dermatol 2006, 155:999-1005
46. Mertens F, Fletcher CD, Dal Cin P, De Wever I, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van den Berghe H, Vanni R, Willén H: Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer 1998, 22:16-25
47. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M: Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003, 201:487-495
48. el-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S: DNA copy number changes in gastrointestinal stromal tumors: a distinct genetic entity. Ann Chir Gynaecol 1998, 87:287-290
49. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221
50. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA: Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998, 17:4657-4667
51. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA: Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444:61-66
52. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007, 121:199-205
53. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J: Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002, 133:105-111
54. Hermeking H: p53 enters the microRNA world. Cancer Cell 2007, 12:414-418
55. Bailey SG, Sanchez-Elsner T, Stephanou A, Cragg MS, Townsend PA: Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 2010, 15:541-552
56. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM: p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006, 58:190-207